Clinical Trial Detail

NCT ID NCT02616185
Title A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Pfizer

prostate cancer


PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab

Age Groups: adult

No variant requirements are available.